Sitemap

Search

Search
Ingredients Name

‘’ 에 대한 검색결과 (33)

  • ETC

Neonypol Vaginal Soft Cap.

Active Ingredients
Nystatin 100000 IU + Neomycin Sulfate 50.2mg + Polymixin B Sulfate 35000 IU
Indications
Vaginal candidiasis, non-specific bacterial vaginitis, vulvitis, and purulent leukorrhea due to stomach disease
  • ETC

Newlocam Cap.

Active Ingredients
Meloxicam 7.5mg
Indications
1. Treatment of short-term symptoms in acute exacerbation of osteoarthritis with ataxia of pain 2. Symptomatic treatment of rheumatoid arthritis over a long period of time 3. Symptomatic treatment of ankylosing spondylitis
  • ETC

Procin Eye Drops

Active Ingredients
Levofloxacin Hydrate 5mg/mL
Indications
1. Effective species Staphylococcus, streptococcus, pneumococcus, micrococcus, enterococci, corynebacterium, pseudomonas, stenotropomonas (santomonas) maltophilia, pseudomonas aeruginosa, haemophilus [haemophilus influenzae, haemophilus aegyptius (Koch-Weeks)], moraxella, ceratia, klebsiella, proteus, morganella morgani, acinetobacter, enterobacter, acne bacteria 2. Indications Blepharitis, erythroma, folliculitis, conjunctivitis, scleritis, keratitis, corneal ulcer, aseptic therapy during ophthalmic surgery
  • ETC

Ratrol Inj.

Active Ingredients
Tramadol HCl 50mg/mL / Tramadol HCl 100mg/2mL
Indications
1. Severe and moderate acute pain (various cancers) 2. Diagnosis and post-operative pain
  • ETC

Rosutatin Tab. 10mg

Active Ingredients
Rosuvastatin 10mg
Indications
1. Primary hypercholesterolemia (type Ⅱa including heterozygous familial hypercholesterolemia), complex hyperlipidemia (type Ⅱb): Dietary supplements if they cannot be controlled by diet and exercise 2. Adjuvant of diet or other lipid-lowering therapy (eg, LDL separation) for homozygous familial hypercholesterolemia 3. Delayed progression of atherosclerosis in patients with hypercholesterolemia by lowering total cholesterol and LDL-cholesterol to target levels 4. Dierary supplements to reduce chloesterol, LDL-cholesterol and Apo-B protein levels in patients aged 10 ~ 17 years (female at least one year after menarche) with heterozygous family hypercholesterolemia, which still meets the following criteria, despite the diet 1) LDL-cholesterol still exceeds 190 mg/dL (LDL-C>190 mg/dL) 2) LDL-cholesterol still exceeds 160 mg/dL (LDL-C>160 mg/dL), with a family history of early cardiovascular disease or at least two cardiovascular disease risk factors 5. Dietary supplements in patients with primary abnormal betalipoproteinemia (type III) 6. Reduced risk of cardiovascular disease: There is no clinical evidence of coronary heart disease, but men over 50 years of age and women over 60 years of age have a high sensitivity of C-reactive protein (hsCRP) of 2 mg/L and at least one additional cardiovascular risk factor (eg, high blood pressure, low HDL-cholesterol levels, smoking, or family history of early coronary heart disease); 1) Reduced risk of stroke 2) Reduced risk of myocardial infarction 3) Reduced risk of arterial angioplasty
  • ETC

Rosutatin Tab. 20mg

Active Ingredients
Rosuvastatin 20mg
Indications
1. Primary hypercholesterolemia (type Ⅱa including heterozygous familial hypercholesterolemia), complex hyperlipidemia (type Ⅱb): Dietary supplements if they cannot be controlled by diet and exercise 2. Adjuvant of diet or other lipid-lowering therapy (eg, LDL separation) for homozygous familial hypercholesterolemia 3. Delayed progression of atherosclerosis in patients with hypercholesterolemia by lowering total cholesterol and LDL-cholesterol to target levels 4. Dierary supplements to reduce chloesterol, LDL-cholesterol and Apo-B protein levels in patients aged 10 ~ 17 years (female at least one year after menarche) with heterozygous family hypercholesterolemia, which still meets the following criteria, despite the diet 1) LDL-cholesterol still exceeds 190 mg/dL (LDL-C>190 mg/dL) 2) LDL-cholesterol still exceeds 160 mg/dL (LDL-C>160 mg/dL), with a family history of early cardiovascular disease or at least two cardiovascular disease risk factors 5. Dietary supplements in patients with primary abnormal betalipoproteinemia (type III) 6. Reduced risk of cardiovascular disease: There is no clinical evidence of coronary heart disease, but men over 50 years of age and women over 60 years of age have a high sensitivity of C-reactive protein (hsCRP) of 2 mg/L and at least one additional cardiovascular risk factor (eg, high blood pressure, low HDL-cholesterol levels, smoking, or family history of early coronary heart disease); 1) Reduced risk of stroke 2) Reduced risk of myocardial infarction 3) Reduced risk of arterial angioplasty
  • ETC

Rosutatin Tab. 5mg

Active Ingredients
Rosuvastatin 5mg
Indications
1. Primary hypercholesterolemia (type Ⅱa including heterozygous familial hypercholesterolemia), complex hyperlipidemia (type Ⅱb): Dietary supplements if they cannot be controlled by diet and exercise 2. Adjuvant of diet or other lipid-lowering therapy (eg, LDL separation) for homozygous familial hypercholesterolemia 3. Delayed progression of atherosclerosis in patients with hypercholesterolemia by lowering total cholesterol and LDL-cholesterol to target levels 4. Dierary supplements to reduce chloesterol, LDL-cholesterol and Apo-B protein levels in patients aged 10 ~ 17 years (female at least one year after menarche) with heterozygous family hypercholesterolemia, which still meets the following criteria, despite the diet 1) LDL-cholesterol still exceeds 190 mg/dL (LDL-C>190 mg/dL) 2) LDL-cholesterol still exceeds 160 mg/dL (LDL-C>160 mg/dL), with a family history of early cardiovascular disease or at least two cardiovascular disease risk factors 5. Dietary supplements in patients with primary abnormal betalipoproteinemia (type III) 6. Reduced risk of cardiovascular disease: There is no clinical evidence of coronary heart disease, but men over 50 years of age and women over 60 years of age have a high sensitivity of C-reactive protein (hsCRP) of 2 mg/L and at least one additional cardiovascular risk factor (eg, high blood pressure, low HDL-cholesterol levels, smoking, or family history of early coronary heart disease); 1) Reduced risk of stroke 2) Reduced risk of myocardial infarction 3) Reduced risk of arterial angioplasty
  • ETC

Serokfen Tab.

Active Ingredients
Loxoprofen Sodium Hydrate 68.1mg
Indications
1. Anti-inflammatory and analgesic of the following diseases and symptoms Chronic rheumatoid arthritis, osteoarthritis (degenerative arthritis), low back pain, frozen shoulder, cervical syndrome 2. Anti-inflammatory and analgesic after surgery, after trauma and extraction 3. Antipyretic and analgesia of the following diseases Acute upper respiratory tract infection (including acute upper respiratory tract infection with acute bronchitis)
FIRST 1 2 3 4 5 LAST